K. P. Johnson

University of Maryland, Baltimore — United States

Medicine · Health Sciences

23h-index4.7kcitations45works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(26), Virology and Viral Diseases(11), Peripheral Neuropathies and Disorders(10), Polyomavirus and related diseases(9), Viral Infections and Immunology Research(6)

Publications45 total

Transcriptomic Profiles Associated with Experimental Placebo Effects in Chronic Pain
Clinical Pharmacology & Therapeutics·2024· 5 citedOpen Access
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
Multiple Sclerosis Journal·2010· 206 citedOpen Access
Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis
Multiple Sclerosis Journal·2007· 42 cited
Whose Wishes and Feelings? Children's Autonomy and Parental Influence in Family Court Enquiries
The British Journal of Social Work·2006· 26 cited
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
Multiple Sclerosis Journal·2006· 138 cited
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
Acta Neurologica Scandinavica·2004· 70 cited
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
Multiple Sclerosis Journal·2003· 55 cited
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years
Journal of the Neurological Sciences·2002· 45 cited
Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
Multiple Sclerosis Journal·2001· 104 cited
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
Multiple Sclerosis Journal·2001· 80 cited
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Multiple Sclerosis Journal·2000· 227 cited
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Multiple Sclerosis Journal·2000· 188 cited
The effect of vesnarinone on TNFα production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis
Journal of Neuroimmunology·1999· 11 cited
The relationship of MS to physical trauma and psychological stress [RETIRED]
Neurology·1999· 115 citedOpen Access
Role of interferons in demyelinating disease
1997· 1 cited
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Neurology·1995· 1.9k cited
A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Archives of Neurology·1994· 60 cited
The effects of 4‐aminopyridine in multiple sclerosis patients
Neurology·1994· 154 cited
Interferon therapy for multiple sclerosis.
PubMed·1992· 12 cited
Tumor necrosis factor identified in multiple sclerosis brain.
The Journal of Experimental Medicine·1989· 796 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Corey C. Ford(7), Robert P. Lisak(7), Hillel Panitch(7), J. S. Wolinsky(6), Lawrence W. Myers(5), John Rose(5), Suhayl Dhib‐Jalbut(5), Arthur Ginsberg(5), Benjamin Brooks(4), Andrew Goodman(4), Amy A. Pruitt(4), Erling Norrby(4), Norman J. Kachuck(3), Jerry S. Wolinsky(3), Roland Martinꝉ(3), Peggy Swoveland(3), Donald R. Carrigan(3), Natalie E. Cremer(3), L. P. Weiner(2), Joseph Guarnaccia(2)